With Novartis (NYSE: NVS )
in the midst of a business transformation process and management
projecting significant improvements, investors are a little less
interested in quarterly results for the time being. Results for the
second quarter were OK, but sluggish growth in Pharma highlights the
importance of good clinical data on LCZ696 in heart failure and progress
over the next 12 months in the immuno-oncology portfolio.
The Street is pretty bullish on these shares, though the
performance on a year-to-date basis has been more middle of the road
between the likes of Merck (NYSE: MRK ) , Bristol-Myers (NYSE: BMY ) , Pfizer, and Roche.
It would seem that a lot of optimism on LCZ696 and margin improvements
is getting worked into the shares and while stronger-than-expected data
on LCZ696 and/or the immuno-oncology portfolio would be well-received, I
think investors already expect more from Novartis than virtually any
other Big Pharma company.
Read more here:
Forget Earnings: Catalysts Incoming for Novartis Stock
No comments:
Post a Comment